Last reviewed · How we verify
human cord blood mononuclear cells
At a glance
| Generic name | human cord blood mononuclear cells |
|---|---|
| Also known as | Group 1 |
| Sponsor | Shenzhen Beike Bio-Technology Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis (PHASE1)
- Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke (PHASE1)
- Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children (PHASE1)
- Human Cord Blood Mononuclear Cells in the Treatment of Refractory Diabetic Foot (NA)
- Clinical Application and Mechanism of Cord Blood Mononuclear Cells in the Treatment of Ischemic Bowel Disease (NA)
- Safety of Autologous Cord Blood Cells in HLHS Patients During Norwood Heart Surgery (PHASE1)
- UCB Stem Cells for Autism Spectrum Disorders (PHASE1)
- Allogeneic Cord Blood Cells for Adults With Severe Acute Contusion Spinal Cord Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |